These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 17573127)

  • 1. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation.
    Rollema H; Coe JW; Chambers LK; Hurst RS; Stahl SM; Williams KE
    Trends Pharmacol Sci; 2007 Jul; 28(7):316-25. PubMed ID: 17573127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of varenicline for smoking cessation.
    Hays JT; Ebbert JO; Sood A
    Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.
    Foulds J
    Int J Clin Pract; 2006 May; 60(5):571-6. PubMed ID: 16700857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New drugs; varenicline].
    van Bronswijk H; Dubois EA; Zitman FG; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(45):2503-4. PubMed ID: 18062594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
    Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
    Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review.
    Crunelle CL; Miller ML; Booij J; van den Brink W
    Eur Neuropsychopharmacol; 2010 Feb; 20(2):69-79. PubMed ID: 19959340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
    Lam S; Patel PN
    Cardiol Rev; 2007; 15(3):154-61. PubMed ID: 17438382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
    Coe JW; Brooks PR; Vetelino MG; Wirtz MC; Arnold EP; Huang J; Sands SB; Davis TI; Lebel LA; Fox CB; Shrikhande A; Heym JH; Schaeffer E; Rollema H; Lu Y; Mansbach RS; Chambers LK; Rovetti CC; Schulz DW; Tingley FD; O'Neill BT
    J Med Chem; 2005 May; 48(10):3474-7. PubMed ID: 15887955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New tobacco dependence drug: Varenicline, partial agonist of alpha4beta2 acetylcholine-nicotine receptors].
    Králíková E
    Cas Lek Cesk; 2006; 145(11):832-4. PubMed ID: 17168413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varenicline for smoking cessation.
    Tonstad S
    Expert Rev Neurother; 2007 Feb; 7(2):121-7. PubMed ID: 17286546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
    Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
    Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.
    Mihalak KB; Carroll FI; Luetje CW
    Mol Pharmacol; 2006 Sep; 70(3):801-5. PubMed ID: 16766716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness and safety of varenicline for smoking cessation].
    Christalla P; Dewenter M; El-Armouche A
    Dtsch Med Wochenschr; 2012 May; 137(18):940-4. PubMed ID: 22492478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
    Rollema H; Hurst RS
    Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced affective symptoms during tobacco dependence treatment with varenicline.
    Grosshans M; Mutschler J; Hermann D; Mann K; Diehl A
    Addiction; 2009 May; 104(5):859-61. PubMed ID: 19413797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats.
    Paterson NE; Min W; Hackett A; Lowe D; Hanania T; Caldarone B; Ghavami A
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1455-64. PubMed ID: 20708056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Varenicline in smoking cessation.
    Tonstad S; Rollema H
    Expert Rev Respir Med; 2010 Jun; 4(3):291-9. PubMed ID: 20524911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Varenicline: for smoking cessation.
    Rao J; Shankar PK
    Kathmandu Univ Med J (KUMJ); 2009; 7(26):162-4. PubMed ID: 20071853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Varenicline--a new chance for smokers?].
    Goniewicz ML; Koszowski B; Czogała J; Sobczak A
    Przegl Lek; 2007; 64(10):899-902. PubMed ID: 18409337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.